1. Home
  2. AIXC vs GRDX Comparison

AIXC vs GRDX Comparison

Compare AIXC & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIXC

AIxCrypto Holdings Inc.

N/A

Current Price

$1.29

Market Cap

27.9M

Sector

Health Care

ML Signal

N/A

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$6.22

Market Cap

28.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIXC
GRDX
Founded
1996
N/A
Country
United States
United Kingdom
Employees
10
2
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.9M
28.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AIXC
GRDX
Price
$1.29
$6.22
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
41.4K
164.3K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$1.87
52 Week High
$2.98
$6.93

Technical Indicators

Market Signals
Indicator
AIXC
GRDX
Relative Strength Index (RSI) 48.57 71.45
Support Level $1.18 $2.16
Resistance Level $1.48 $6.93
Average True Range (ATR) 0.10 0.64
MACD -0.00 0.11
Stochastic Oscillator 38.71 78.03

Price Performance

Historical Comparison
AIXC
GRDX

About AIXC AIxCrypto Holdings Inc.

AIxCrypto Holdings Inc is a technology infrastructure company focused on the convergence of artificial intelligence and blockchain-based programmable systems. The Company develops software platforms and programmable infrastructure designed to facilitate the tokenization of real-world assets (RWA) and the deployment of Embodied Artificial Intelligence (EAI) in commercial environments. Its mission is to serve as the regulated, programmable infrastructure layer connecting traditional capital markets with on-chain systems and AI-enabled commercial systems.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: